05.03.19: Not intended for U.S. and UK Media

Bayer submits darolutamide for marketing authorization in JapanRegulatory submission based on positive data from Phase III ARAMIS studymehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news